Close Menu

NEW YORK (360Dx) – Akers Biosciences announced today that it has signed a three-year agreement with the Greater New York Hospital Association — a trade and group purchasing association representing hospitals and healthcare systems in New York, New Jersey, Connecticut, and Rhode Island.

As part of the agreement, Akers Biosciences will market its rapid tests for heparin-induced thrombocytopenia to the association’s 300 hospitals.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.